Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy

Spero Therapeutics, Inc. ( SPRO ) is a biopharmaceutical company that develops tebipenem HBr (Tebi). This is an investigational oral carbapenem for complicated urinary tract infection (cUTI), including pyelonephritis. Their Phase 3 trial (PIVOT-PO) met its primary endpoint and was stopped early after aMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio Un ...